Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 3Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 1Castration-resistant Prostate Cancer 1Castration Resistant Metastatic Prostate Cancer 1

Interventions

pembrolizumab 223Carboplatin 222Specimen Handling 194Cisplatin 192Magnetic Resonance Spectroscopy 165Radiotherapy 153Bevacizumab 143Gemcitabine 136Cyclophosphamide 135Drug Therapy 119Capecitabine 118Paclitaxel 116Oxaliplatin 111Nivolumab 105Biopsy 104venetoclax 103tislelizumab 83Rituximab 83durvalumab 82toripalimab 78Fluorouracil 73Etoposide 72Docetaxel 69Dexamethasone 69sintilimab 67Pemetrexed 67atezolizumab 65Radiosurgery 65Azacitidine 63130-nm albumin-bound paclitaxel 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × testosterone enanthate × Clear all
NCT06594926 2026-04-24

WOMBAT

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Recruiting
69 enrolled
Genitourinary

Prostatic Neoplasms

NCT03522064 2026-04-23

HiTeCH

St Vincent's Hospital, Sydney

Phase 2 Recruiting
30 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT04363164 2026-04-06

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
150 enrolled
Genitourinary

Castration Resistant Metastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡